Clostridium hiranonis Markers for Canine Diet-Responsive Enteropathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel methods and compositions to treat inflammatory bowel disease (IBD) and other intestinal disorders that target the gut microbiome and its metabolites, as existing treatments are inadequate in addressing the multi-factorial nature of these conditions.
Innovation Solution
A method for determining a companion animal's responsiveness to a therapeutic hydrolyzed protein diet by measuring intestinal microorganisms, specifically those producing bile acids, and administering the diet or additional treatments based on their abundance relative to reference amounts, along with health assessment tools to monitor intestinal health.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a therapeutic hydrolyzed protein diet is administered to treat chronic enteropathy, then intestinal health improves and remission is achieved, but the method requires precise measurement and identification of specific intestinal microorganisms to determine responsiveness
Solution Approach 1:
The patent replaces complex mechanical/physical measurement systems with molecular biology techniques. Specifically, it uses 16S rRNA gene sequencing to detect and quantify specific intestinal microorganisms (such as Clostridium hiranonis) rather than relying on traditional culturing or physical measurement methods. This substitution enables more precise and reliable identification of microbial markers associated with diet responsiveness in chronic enteropathy patients.
Solution Approach 2:
The patent introduces 16S rRNA gene sequences as intermediary markers to indirectly assess intestinal microorganism composition. Instead of directly measuring complex microbial communities, the method uses specific rRNA sequences (such as those of Clostridium hiranonis with sequence FJ957494.1.1454) as proxies to determine dietary responsiveness. This intermediary approach simplifies the measurement process while maintaining diagnostic accuracy.
2Reliability
If the method measures specific intestinal microorganisms to determine diet responsiveness, then treatment effectiveness is improved, but the complexity of the diagnostic process increases
Solution Approach 1:
The patent segments the complex intestinal microbiome into specific, identifiable markers. Instead of analyzing the entire microbial community at once, the method focuses on detecting specific 16S rRNA sequences (such as Clostridium hiranonis FJ957494.1.1454) that are associated with diet responsiveness. This segmentation allows for targeted detection using specific primers and sequencing protocols, reducing the overall complexity of the diagnostic process while maintaining high reliability in predicting treatment outcomes.
Solution Approach 2:
The patent changes the measurement parameter from general microbial community structure to specific molecular sequences (16S rRNA). By transforming the diagnostic approach into a molecular-level analysis of specific gene sequences, the method achieves more reliable predictions of diet responsiveness. The use of sequence-based identification (such as comparing against reference sequences like FJ957494.1.1454) provides a standardized, reproducible parameter that simplifies the diagnostic workflow while improving treatment effectiveness.
3Measurement precision
If reference amounts of intestinal microorganisms are used for comparison, then diagnostic accuracy is improved, but the requirement for healthy control data increases the study complexity
Solution Approach 1:
The patent performs preliminary characterization of intestinal microorganisms in healthy control animals before diagnosing chronic enteropathy patients. By first establishing the baseline 16S rRNA sequence profiles and abundance patterns in healthy dogs (such as the reference Clostridium hiranonis sequence FJ957494.1.1454), the method creates a benchmark for comparison. This preliminary action enables accurate diagnostic differentiation between healthy and dise states, improving measurement precision without requiring complex real-time analysis during patient diagnosis.
Data Source
Figure 1A~1C
Figure 2A
Figure 2B~2F
AI summary
The presently disclosed subject matter relates to method, compositions and food products for improving intestinal health, treating intestinal dysbiosis and/or treating an intestinal disorder in a subject, e.g., a human or a companion animal.